New Factor XIa Inhibitor Cuts Stroke Risk With Lower Bleeding: Phase III Win
Alex So, Associate Director Strategy and Digitalisation China at Merck Group, posted on LinkedIn:
”Rather than a discouraging attempt that the quoted video may suggest, it is delightful to know the factor XIa inhibitor’s potential to reduce stroke risk in patients who have had a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, as reported by its latest phase III trial for secondary stroke prevention.
Factor XIa can activate Factor IX, amplifying thrombin generation of the clotting process. As an anticoagulation strategy, the inhibition has less impact on clot stabilisation in response to injury, i.e., a lower risk of bleeding. It might be worth rementioning the siRNA drug that silences the gene producing antithrombin, a mechanism in this field applicable to haemophilia as discussed in a prior post.
The milestone success, which enables continued efforts to develop a better blood thinner despite a somewhat reduced scope and to investigate Factor XIa as a target, is encouraging.
Non-business-related therapeutics posting. Consult practitioners for medication needs.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies